3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Neoplasm Metastasis
33
Leukemia, Myeloid, Acute
24
Melanoma
14
Colorectal Neoplasms
14
Breast Neoplasms
14
Multiple Myeloma
13
Myelodysplastic Syndromes
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Pancreatic Neoplasms
10
Lymphoma, Follicular
10
Prostatic Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Large B-Cell, Diffuse
8
Triple Negative Breast Neoplasms
7
Lymphoma, Non-Hodgkin
7
Lymphoma, Mantle-Cell
7
Lung Neoplasms
7
Burkitt Lymphoma
7
Ovarian Neoplasms
6
Lymphoma, B-Cell, Marginal Zone
6
Stomach Neoplasms
5
Sarcoma
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, T-Cell
5
Lymphoma, B-Cell
5
Lymphoma
5
Leukemia, Biphenotypic, Acute
5
Carcinoma, Renal Cell
5
Carcinoma, Non-Small-Cell Lung
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Interventions
peginesatide
2
hematide
2
Lenalidomide
2
venetoclax
1
trametinib
1
ruxolitinib
1
reolysin
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
neratinib
1
lorlatinib
1
lenvatinib
1
iron isomaltoside 1000
1
idelalisib
1
enzalutamide
1
entrectinib
1
enasidenib
1
durvalumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
dehydroftorafur
1
darolutamide
1
dacomitinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Anemia
×
Biopsy
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled